Testing effectiveness (Phase 2)Ended earlyNCT01025232
What this trial is testing
Intravitreal Injections of 2.0mg Ranibizumab in Subjects With Chronic Fluid On OCT Post Multiple Injections With Ranibizumab (Super-dose Anti-VEgf SAVE Trial)
Who this might be right for
Age Related Macular DegenerationChoroidal Neovascular MembraneSubfoveal Neovascular Age-Related Macular Degeneration+2 more
David M. Brown, M.D. 88